Evidence map›Paper›PMID 21074441›Full record

ArticleTrends in cell biology2011

Inactive yet indispensable: the tale of Jarid2.

David Landeira, Amanda G Fisher

Open access · hybridAbstract read
In one paragraph

Article in Trends in cell biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. JMJD family proteins in cancer and inflammation.Signal transduction and targeted therapy · 2022
    Review
  12. Epigenetic Mechanisms of Epidermal Differentiation.International journal of molecular sciences · 2022
    Review
  13. TruncatedScience advances · 2022
    Article
  14. Article
  15. Peritoneal Modulators of EZH2-miR-155 Cross-Talk in Endometriosis.International journal of molecular sciences · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David LandeiraLymphocyte Development Group, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.
Amanda G Fisher
Hammersmith Hospital · GB

Funding

Medical Research Council MC_U120027516
6 · The paper itself

Abstract

Methylation of histone tails is believed to be important for the establishment and inheritance of gene expression programs during development. Jarid2/Jumonji is the founding member of a family of chromatin modifiers with histone demethylase activity. Although Jarid2 contains amino acid substitutions that are thought to abolish its catalytic activity, it is essential for the development of multiple organs in mice. Recent studies have shown that Jarid2 is a component of the polycomb repressive complex 2 and is required for embryonic stem (ES) cell differentiation. Here, we discuss current literature on the function of Jarid2 and hypothesize that defects resulting from Jarid2 deficiency arise from a failure to correctly prime genes in ES cells that are required for later stages in development.

Indexed as

Amino Acid SequenceAnimalsEmbryo, MammalianEmbryonic Stem CellsHistone DemethylasesHumansMiceMolecular Sequence DataNerve Tissue ProteinsPolycomb-Group ProteinsPolycomb Repressive Complex 2Repressor ProteinsSequence AlignmentHistone DemethylasesJarid2 protein, mouseNerve Tissue ProteinsPolycomb-Group ProteinsPolycomb Repressive Complex 2Repressor Proteins

Identifiers

PMID21074441
PMCPMC3034028
OpenAlexW2045781791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.